Notícias

Add another member to the fast-and-furious AI unicorn club: Simile

CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.

Knorr-Bremse AG (KNRRY) achieves highest quarterly operating EBIT margin in five and a half years, while launching a 'Growth Beyond' strategy targeting EUR10 billion in revenue by 2030.

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

X sued the WFA in 2024 for conducting what it called a "systematic illegal boycott" of the platform after it saw a decline in advertising revenue following Musk's $44 billion takeover of the social network

July 29 (Reuters) - SpaceX's X and the World Federation of Advertisers (WFA) said on Wednesday they had settled litigation over an alleged advertiser boycott of the social media platform linked to the

CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.

(Bloomberg) -- Executives and investors tied to the AI supply chain were among the biggest insider sellers in the second quarter, taking advantage of a sharp — and volatile — rally in technology stocks.Most Read from BloombergUS Intercepts Iran Attack on Bases, Puncturing Days of CalmSK Hynix Profit Disappoints, Spending Soars to $31 BillionNvidia’s $750 Billion in Deals Reignite Circular AI FearsChip Rout Deepens on Circular Funding, China Competition FearsApple Set to Make Big Smart Home Push

CVS Health opened new pharmacy focused CVS Pharmacy locations in smaller, neighborhood formats across the United States. The company began offering the Kate Farms High Protein Nutrition Shake on shelves nationwide in CVS stores. These moves expand CVS Health's physical footprint and its presence in the wellness and nutrition category. CVS Health (NYSE: CVS) is adding fresh operational moves on top of a strong recent share price run. The stock trades at $109.34 and is up 36.5% year to date,...

CVS Health (CVS) closed the most recent trading day at $109.34, moving +2.12% from the previous trading session.

Administration officials told the Wall Street Journal that the subsidy program that has helped suppress Medicare Part D prescription drug plan premiums will not be renewed for 2027.

Humana reports earnings Wednesday after its stock surged this year on improving confidence in Medicare Advantage insurers. Investors will be watching medical costs and the company’s outlook.

HSIC heads into Q2 earnings with expectations for revenue and EPS growth as dental, specialty products and AI-enabled technology remain in focus.

CVS Health has rallied the broader market over the past year, and analysts remain highly optimistic about the stock’s prospects.

CVS, CAH, HUM and ACAD show favorable earnings indicators ahead of Q2 results as healthcare demand stays resilient despite margin pressures.

UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

CVS, CAH, HUM and ACAD look ready for Q2 2026 earnings beats as growing demand for medical products and services continues to support performance.

(Bloomberg) -- US companies that are integrating artificial intelligence capabilities are well positioned this earnings season as they’re poised for stronger profit margins, according to Morgan Stanley strategists.Most Read from BloombergDeepSeek Suspends Fundraising After Viral US-China PostsUS, Iran Extend Pause in Strikes as Oman Holds Hormuz TalksSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysChina Chipmaker CXMT Jumps 466% in Debut After Blockbuster IPOStocks, Bonds Rise in Re

They are riding strong tailwinds that could lift them higher.

The healthcare giant looks expensive on today's numbers, but a patient investor is effectively buying it at a significant discount to that price.

HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CVS Health stock has surged nearly 80% in a year while the quarterly dividend has sat frozen for ten straight quarters, raising a pointed question for income investors: is this pause a sign of discipline or a warning.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Henry Ford Health has filed a lawsuit against CVS Health (NYSE:CVS) alleging fraudulent reimbursement practices tied to the federal 340B drug discount program. The complaint claims CVS manipulated pricing and engaged in retaliatory behavior, which Henry Ford Health says led to losses of more than US$29 million. The case adds to a series of disputes between large health systems and pharmacy operators over how 340B program discounts are administered. For investors following CVS Health, this...

CVS Health is in focus after a modest reset to its price target framework, with the updated intrinsic value estimate moving from US$107.73 to US$111.92, a change of about 3.9%. This shift sits alongside Street commentary that ties higher price objectives to views on Medicare Advantage execution, pharmacy and pharmacy benefit manager performance, and GLP-1 related efforts, while still flagging policy and utilization trends as key swing factors. As you read on, you will see how these evolving...

Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.

CVS Group (LON:CVSG) said revenue for the financial year ended June 30 exceeded GBP 710 million, up 5.9% from the prior year, as the veterinary services provider used an investor presentation to reiterate its capital allocation policy and outline expected returns from acquisitions and capital invest

Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.